Precigen Inc. Common Stock (PGEN)
Stock · NASDAQ · Health Care
$6.39as of 10/16/2026
Price chart
Active signals
PGEN Signal Track Record
How signals performed across all stocks →What PGEN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +6.4% | 55% | September 30, 2026 |
| Bollinger Band Breakout | 31 | +3.7% | 58% | September 17, 2026 |
| Bollinger Band BreakdownActive now | 17 | +8.2% | 53% | June 2, 2026 |
| 200-Day Moving Average TouchActive now | 11 | +10.8% | 55% | March 6, 2026 |
| Any 20-session window (baseline) | +4.0% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PGEN
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 160
- Website
- precigen.com/
Fundamentals
- 1-day range
- $6.82$7.22
- Market cap
- $2.47B
- P/E (trailing)
- —
- P/E (forward)
- -31.02
- EPS (trailing)
- $-0.52
- Dividend yield
- —
- Beta
- 0.99
- Avg. volume
- 5.04M
How Precigen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Precigen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PGENPrecigen Inc. Common Stock$6.39▼ 11.25%Market cap $2.47BP/E —$3.04$8.98
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
- KLRAKailera Therapeutics Inc. Common Stock$11.25▼ 3.93%Market cap $2.44BP/E —$9.76$28.23
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- PHVSPharvaris N.V. Ordinary Shares$27.74▼ 6.41%Market cap $2.40BP/E —$20.65$43.25
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PGEN Precigen Inc. Common Stock | $2.47B | — | $6.39 | ▼ 11.25% | $3.04$8.98 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
| KLRA Kailera Therapeutics Inc. Common Stock | $2.44B | — | $11.25 | ▼ 3.93% | $9.76$28.23 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| PHVS Pharvaris N.V. Ordinary Shares | $2.40B | — | $27.74 | ▼ 6.41% | $20.65$43.25 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?Yahoo · 9/26/2026
- MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?Yahoo · 9/25/2026
- Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future TherapiesYahoo · 9/25/2026
- ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary GoalYahoo · 9/25/2026
- LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2DYahoo · 9/25/2026
- Merck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyYahoo · 9/25/2026
- This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga · 9/25/2026
- This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 9/25/2026
- B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12Benzinga · 9/25/2026
Insider Activity
Insider Actions →- Harry Thomasian Jr. · September 23, 2026 · Option Exercise1 @ $1.21
- Harry Thomasian Jr. · September 23, 2026 · Option Exercise2 @ $0.96
- Harry Thomasian Jr. · September 23, 2026 · Option Exercise42.9K @ $2.33
- Harry Thomasian Jr. · September 23, 2026 · Option Exercise10.7K @ $4.72
- Jeffrey B. Kindler · August 26, 2026 · Sale185.0K @ $7.44
- Rutul R. Shah · August 25, 2026 · Option Exercise15.3K @ $2.33
- Rutul R. Shah · August 25, 2026 · Sale15.3K @ $7.5
- Phil Tennant · August 25, 2026 · Option Exercise79.2K @ $1.61
- Phil Tennant · August 25, 2026 · Sale79.2K @ $7.5
- Donald P. Lehr · August 23, 2026 · Option Exercise5.2K
- Donald P. Lehr · August 23, 2026 · Tax Withholding2.5K @ $7.2
- Harry Thomasian Jr. · August 23, 2026 · Option Exercise7.3K
- Harry Thomasian Jr. · August 23, 2026 · Tax Withholding3.6K @ $7.2
- Rutul R. Shah · August 23, 2026 · Option Exercise7.5K
- Rutul R. Shah · August 23, 2026 · Tax Withholding3.6K @ $7.2
Institutional Ownership
March 31, 2026
- Total shares held
- 131.60M
- Total value held
- $504.18M
- Institutional holders
- 197
- Unknown17.82M
- Unknown15.22M
- Unknown10.89M
- Unknown7.15M
- Unknown6.80M
- Unknown6.74M
- Unknown6.42M
- Unknown4.61M
- Unknown4.27M
- Unknown3.59M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog
Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.